

31 May 2020 |

APAC Podcast: Virus Industry Impact, China Vaccines, Remdesivir Deals, Korea SitRep

by Ian Haydock

Join *Scrip* and the *Pink Sheet*'s Asia content team for a wide-ranging look at the ongoing multiple impacts of the pandemic on the pharma industry.

In the third in a popular new series of podcasts, the Asia-based content team for *Scrip* and the *Pink Sheet* dissect some of the major events shaping the regional pharma industry over the past few weeks. Unsurprisingly, the coronavirus outbreak remains top of the list.

Join Anju Ghangurde and Vibha Ravi in Mumbai, Brian Yang in Beijing, Jung Won Shin in Seoul and Ian Haydock in Tokyo for a top-line overview of selected key developments.

[Click here to explore this interactive content online](#) ✎

How Has The Pandemic Played Out in Company Earnings?

Major Indian and Japanese companies have now reported their annual results for the fiscal year ended 31 March, the end of which overlapped with the full emergence of the virus. Anju and Ian look at the varied business impact so far and what the rest of the year might hold. Are there any common themes emerging?

The Latest In China Vaccine Developments

Multiple Chinese companies are among the global front-runners in the development of a

possible vaccine against SARS-CoV-2. Brian takes us on a tour of local and international R&D developments in the field, and some of the challenges facing developers. (Starts at 11'30")

What Does Gilead's Remdesivir Licensing Deal Mean For Prices And Access?

Gilead's existing antiviral remdesivir is receiving much attention as a potential drug treatment, although clear evidence of its efficacy and safety is still emerging. The US firm recently signed a no-royalty deal with multiple companies in India and Vibha breaks down what this might mean for the production, pricing and global access of the drug. (Starts at 18'10")

How Is Korea Coping With The Outbreak?

South Korea has received global praise for its adroit handling of the pandemic, although it is now facing challenges from the emergence of cluster outbreaks after reopening. Meanwhile, the local pharma industry has responded with R&D into both drugs and vaccines. Jung Won explains these issues in her on-the-ground situation update. (Starts at 27'00")

Related Content

(Also see "[Sun Flags Up New Prescriptions Drought Amid COVID-19](#)" - Scrip, 29 May, 2020.)

(Also see "[Takeda Sees Portfolio As Mostly Pandemic-Resistant](#)" - Scrip, 13 May, 2020.)

(Also see "[China Still Leading Vaccines Race Despite Moderna Data, US 'Warp Speed' Plan?](#)" - Scrip, 19 May, 2020.)

(Also see "[Gilead Licensing Deal Expands Remdesivir Access, Capacity](#)" - Scrip, 13 May, 2020.)

(Also see "[How Was Korea Different In Handling COVID-19 Situation?](#)" - Scrip, 12 May, 2020.)